disease classes covered
new data findings/day
patient tests analyzed
Real time access and analysis of over 40 genomic and clinical databases covering over 33,000 diseases.
Advanced analysis, workflow and interpretation software accessing genomic and clinical knowledge from over 20 million references.
Evidence based research, services and advanced software for better decisions.
publications cite QIAGEN’s bioinformatics products as part of their research and clinical insights
Researchers across the world are using QIAGEN Digital Insights solutions to accelerate their work in...
The Winter 2019 Release of the Human Gene Mutation Database (HGMD) Professional is available, expan...
Unlock the power of real-world genomics data with QIAGEN Real-World Insights at the largest annual...
Introduction to de novo transcriptome assembly De novo transcriptome assembly using RNA-seq is a...
Centers for Disease Control and Prevention (CDC) released on November 13, 2019 their report Antibio...
QIAGEN Digital Insights Publication Roundup (Winter 2019/2020)
HGMD 2019.4 Release
Precision Medicine World Conference 2020 in Silicon Valley, CA
De novo transcriptome assembly using QIAGEN CLC Genomics Workbench
QIAGEN CLC Microbial Genomics Module: A valuable tool in the fight against antimicrobial resistance
Targeted NGS panels and optimized analysis and interpretation tools.
Discovery Bioinformatics Services is a reliable and convenient way to extend your in-house resources with expertise and perfectly tailored bioinformatics services that ensure high-quality results.
Enabling pharma companies to develop biomarker diagnostics and targeted therapies using real-world insights from oncology patient genomic data.
Helping clinical testing laboratories leverage the benefits of automation and expert support to improve test turnaround times, enhance clinical reporting capabilities and scale for future growth.
QIAGEN maintains the world’s largest, expert-curated knowledgebase of up-to-date evidence for discovery research, clinical test interpretation and pharmaceutical development.
Interpretation of gene expression data to tackle inflammatory bowel disease
In Germany, scientists tackle cancer cohorts with Sample to Insight QIAGEN tools.
Mount Sinai's novel biomarker predicts treatment outcome in ovarian cancer